Source: Reuters
Security & Justice
Panic Grips Lebanon Amid Evacuation Call Hoax: Who’s Behind the Fear Campaign?
Lebanon witnessed a wave of panic on Friday as residents across various regions received alarming phone calls from foreign numbers warning of imminent Israeli strikes and urging them to evacuate their homes. These warnings, which extended even to areas far from conflict zones, have raised questions about the credibility of the messages and concerns over potential Israeli access to Lebanon's telecommunications infrastructure.
Sunday, November 24, 2024
With Destruction at Lebanon Border, Israel Could Seek Buffer Zone
Israel appears to be trying to create a buffer zone in south Lebanon to remove the threat from Hezbollah but its effectiveness in preventing cross-border attacks remains to be seen, observers say.
Saturday, November 23, 2024
Opinion
Power Vacuum Enables Speaker Berri’s Unchecked Negotiation Role
Ceasefire negotiations between Hezbollah and Israel, spearheaded by Lebanese Parliament Speaker Nabih Berri, have ignited a storm of controversy among political circles, with critics accusing Berri of overstepping constitutional bounds.
Thursday, November 21, 2024
Lebanon's Economy—Not Battlefield—May Have the Final Word
Time and again during this most recent war in Lebanon, we hear the phrase, “The battlefield has the final word”. It has become the sole and wholly unsatisfactory refrain of Hezbollah and the so-called 'Axis of Resistance'.
Wednesday, November 20, 2024
Sports
Israel Face France in Paris Football Match Under Tight Security
Israel face France in a Nations League football match in Paris on Thursday surrounded by a huge security operation to prevent a repetition of the attacks on Israeli fans in Amsterdam last week.
Thursday, November 14, 2024
Alcaraz Beats Rublev to Open ATP Finals Account
Carlos Alcaraz opened his account at the ATP Finals on Wednesday with an entertaining 6-3, 7-6 (10/8) win over Andrey Rublev which boosted his hopes of reaching the semifinals.
Wednesday, November 13, 2024
Tuesday 15 June 2021 12:59:01
AstraZeneca Says Antibody Treatment Failed in Preventing Covid-19 in Exposed Patients
Anglo-Swedish drugmaker AstraZeneca said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic Covid-19 in people recently exposed to the novel coronavirus.
The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the coronavirus within the past eight days.
AZD7442 reduced the risk of developing symptomatic Covid-19 by 33 per cent compared to a placebo, which was not statistically significant, the company reported.
“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen inthe PCR negative participants following treatment with AZD7442,” Mene Pangalos, AstraZeneca executive vice president, said in a statement.
AstraZeneca is also studying the treatment in a pre-exposed patients trial and for preventing more severe disease.
The monoclonal antibody therapy belongs to a class of drugs which mimic natural antibodies the body produces to fight off the infection.
Rivals Regeneron Pharmaceuticals Inc and Eli Lilly& Co have both developed monoclonal antibody therapies which have been authorised for use in the United States to treat patients infected with the virus. The European Medicines Agency (EMA) has approved Regeneron’s therapy and is reviewing similar drugs from Eli Lilly, Celltrion and one developed by GlaxoSmithKline and VirBiotechnology Inc.
AstraZeneca in October enlisted Swiss contract manufacturer Lonza to produce the antibody drug in Portsmouth, NewHampshire, starting in the first half of 2021.
AZD7442 is being developed with support from the US government. AstraZeneca in March announced a deal with the US government to supply up to half a million doses of AZD7442. The company said on Tuesday it is now in talks with the US government regarding next steps on the deal.
